% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Dec 7, 2012 6:36 PM Flag

    Wall Street doesn't like the word "unprecedented"...


    Thanks for the positive reinforcement, urabt2.
    If Ernie's intuitive assertion wrt DTC compendia listing is correct ( I absolutely believe it is...) the shorts have but numbered days to exercise control of EXEL. The more they play, the more I buy. The lower they drive the valuation, the greater the chance of an interventional buy-out. In the midst of a diminished share price, the clinical data just gets better and better...which means that a buy-out valuation has nowhere to go but upward. The clinical positivity is outstanding.

    Cometriq is soon to develop a profound rate of clinical adoption that will rival that of Gleevec, and - as shareholders - we have some off-the-radar NCCN dates of colossal stock valuation importance to recognize. I am still in research to deliver full-length on this topic, and will return to it when my findings are mature enough to share w/ all. The holiday season is simply not the best-of-times for information gathering.
    Cash post-approval bonuses have just today been announced at Exelixis.
    The shareholder bonus party begins in 2013.
    Have a good holiday.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.89+0.15(+1.02%)Sep 23 4:00 PMEDT